Occurrence of active pulmonary tuberculosis
Conditions
Interventions
Intervention group A:Drug A: INH900 mg once weekly for 12 doses (3 months). Drug B: RPT900mg once weekly for 12 doses (3 months)
Intervention group B:Drug A: INH600mg/times, twice a week for 8 weeks. Drug B: RPT600mg/times, twice a week for 8 weeks
Blank control group:Null.
Sponsors
Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College
Eligibility
Sex/Gender
All
Age
50 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. 50-70 years old; 2. Local household registration or resident population; 3. IGRA positivity; 4. Signed voluntarily informed consent.
Exclusion criteria
Exclusion criteria: 1. Past andcurrent tuberculosis patients; 2. Suspected cases of active pulmonary tuberculosis; 3. Pregnant or lactating or preparing for pregnancy; 4. A history of treatment for > 14 consecutive days with a rifapentine or > 30 consecutive days with INH at any time during the 2 years prior to enrollment; 5. Contraindications for taking rifapentine andisoniazid; 6. Abnormal liver function or liver damage and/or with symptoms andsigns of liver damage; 7. HBV or HCV infection; 8. Renal inadequacy or diminished; 9. HIV positivity; 10. Autoimmune diseases or currently receiving immunosuppressive therapy; 11. Alcohol/drug addicts; 12. Mental disorders, deaf/mute disabled who can not cooperate with the study; 13. Others.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Occurrence of active pulmonary tuberculosis; | — |
Countries
China
Contacts
Public ContactLei Gao
Outcome results
None listed